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ABSTRACT
The formation of drug-protein adducts via metabolic activation and
covalent binding may stimulate an immune response or may result in
direct cell toxicity. Protein covalent binding is a potentially pivotal step
in the development of idiosyncratic adverse drug reactions (IADRs).
Trimethoprim (TMP)-sulfamethoxazole (SMX) is a combination antibi-
otic that commonly causes IADRs. Recent data suggest that the
contribution of the TMP component of TMP-SMX to IADRs may be
underappreciated. We previously demonstrated that TMP is
bioactivated to chemically reactive intermediates that can be
trapped in vitro by N-acetyl cysteine (NAC), and we have detected
TMP-NAC adducts (i.e., mercapturic acids) in the urine of patients
taking TMP-SMX. However, the occurrence and extent of TMP
covalent binding to proteins was unknown. To determine the
ability of TMP to form protein adducts, we incubated [14C]TMP
with human liver microsomes in the presence and absence of
NADPH. We observed protein covalent binding that was NADPH
dependent and increased with incubation time and concentration
of both protein and TMP. The estimated covalent binding was
0.8 nmol Eq TMP/mg protein, which is comparable to the level of
covalent binding for several other drugs that have been associ-
ated with covalent binding–induced toxicity and/or IADRs. NAC
and selective inhibitors of CYP2B6 and CYP3A4 significantly
reduced TMP covalent binding. These results demonstrate for
the first time that TMP bioactivation can lead directly to protein
adduct formation, suggesting that TMP has been overlooked as a
potential contributor of TMP-SMX IADRs.
Introduction
Trimethoprim (TMP)-sulfamethoxazole (SMX) is one of the most
commonly prescribed antibiotics worldwide (Van Boeckel et al., 2014).
Although TMP-SMX is considered safe and efficacious, it causes a higher
rate of idiosyncratic adverse drug reactions (IADRs) compared with most
other drugs (Boye and Gaustad, 1991; Macy and Poon, 2009; Björnsson,
2015). SMX is implicated in TMP-SMX–associated IADRs by evidence
of SMX bioactivation, protein adduct formation, and immune stimulation
(Cribb and Spielberg, 1992; Cribb et al., 1997; Naisbitt et al., 2002).
However, SMX alone cannot explain all IADRs to the combination drug,
because TMP (when prescribed alone) has also been associatedwith severe
IADRs and the rates of IADRs are higher for TMP-SMX than for SMX
alone (Harding et al., 1975; Bergan and Skjerven, 1979; Hawkins et al.,
1993; Mortimer et al., 2005).
Although the mechanisms associated with the development of many
IADRs have not been fully elucidated, bioactivation of drugs to reactive
intermediates that covalently bind to proteins is a generally accepted pathway
that can contribute to IADR development (Zhou et al., 2005; Nakayama
et al., 2009; Park et al., 2011; Björnsson, 2015). In general, drugs found to be
more commonly implicated in inducing IADRs tend to exhibit higher in vitro
protein binding compared with those with a lower risk profile (Takakusa
et al., 2008; Nakayama et al., 2009). Thus, a critical step for understanding
the mechanism of TMP-induced IADRs is to determine its potential for
covalent binding to proteins after bioactivation to reactive metabolites.
Recent evidence suggests that TMP undergoes oxidative bioactiva-
tion, either by quinone imine formation or byO-demethylation followed
by quinone methide formation (Lai et al., 1999; Damsten et al., 2008)
(Fig. 1). These in vitro findings are consistent with our recent in vivo
findings of TMP-derived mercapturic acids, such as N-acetyl cysteine
(NAC) conjugates of TMP, in the urine of TMP-SMX–exposed children
and demonstrate for the first time that TMP bioactivation and de-
toxification occurs in humans (van Haandel et al., 2014). Additional
in vitro studies involving human liver microsomes (HLMs), recombi-
nant cytochrome P450s (P450s), and specific P450 inhibitors demon-
strated that CYP3A4 was the primary enzyme contributing to TMP
bioactivation (Goldman et al., 2015). Although these data clearly
demonstrated that TMP undergoes bioactivation in vitro and in human
patients, the extent to which bioactivated TMP metabolites covalently
bind to proteins remained unknown.
The main objective of this work was to characterize the extent of
irreversible covalent binding of TMP to microsomal protein. [14C]-TMP
was synthesized for this purpose, because radiolabeled drugs have
proven to be effective in the estimation of covalent binding to
cellular macromolecules. Inhibition experiments targeting specific
drug-metabolizing enzymes were used to define hepatic enzyme contri-
bution to TMP protein covalent binding, and trapping experiments with
NAC and N-acetyl lysine (NAL) were performed to demonstrate protec-
tion of proteins by surrogate nucleophiles.
Materials and Methods
Materials. EDTA, glucose-6-phosphate dehydrogenase, magnesium chlo-
ride, NAC, NAL, NADP, potassium phosphate dibasic, potassium phosphate
monobasic, TMP, montelukast, quinidine, sulfaphenazole, and 1-benzylimidazole
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were obtained from Sigma-Aldrich Chemical Co. (St. Louis, MO). Benzylnirvanol
and thiotepa were purchased from Toronto Research Chemicals (Toronto, Canada).
Ketoconazolewas obtained fromResearchBiochemicals International (Natick,MA).
Trichloroacetic acid was purchased from Fisher Scientific (Fairlawn, NJ). Pooled
HLMs from 16 donors were purchased from XenoTech, LLC (Lenexa, KS).
Microsomes were stored at280C and placed on ice prior to use, and the same lot of
pooled HLMs was used for all experiments.
[14C]-TMP Synthesis. The synthesis of 2-[14C]-TMP was modeled after the
procedure of Hoffer et al. (1971) (Fig. 2). Themodification was first verified using
nonradioactive materials to give 65%–75% yields of pure TMP (confirmed by
thin-layer chromatography, high-performance liquid chromatography, and high-
resolution mass spectrometry) on the same scale as planned for the radiosynthesis
described below. [14C]-Guanidine hydrochloride (500 mCi, approximately
50 Ci/mol, approximately 9 mmol; Moravek Biochemicals, Brea, CA) was
transferred with 1 ml MeOH into a 13-mm  100-mm culture tube and sodium
methoxide in methanol (1.0 ml, 0.5 M) was added. The mixture was stirred at
70C for 30 minutes. After the reaction mixture was cooled to room temperature,
3-anilino-2-(3,4,5-trimethoxybenzyl) acrylonitrile (48.8 mg, 150 mmol, mixture
of cis/trans isomers; Toronto Research Chemicals) was added in one batch. The
reaction tube was sealed with a screwcap and the mixture was stirred at 70C for
16 hours. The reaction mixture was cooled to room temperature, and guanidine
hydrochloride (9.55 mg, 100 mmol) in 1.0 ml methanol was added to the reaction
mixture and stirred at 70C for another 16 hours. The mixture was cooled to room
temperature and transferred to a 50-ml round-bottom flask and evaporated to
dryness. The residuewas dissolved in 2.5%MeOH in dichloromethane (DCM) and
loaded on a 4-g prepacked silica gel column. The column was washed with DCM
(12ml), 2.5%MeOH/DCM (30ml), and 5%MeOH/DCM (30ml) and the product
was eluted with 10% MeOH/DCM, with monitoring by thin-layer chromatogra-
phy. The combined fraction was evaporated to dryness under a vacuum (yield:
12.8 mg, 44.3 mmol, 41%), which was dissolved inMeOH (10 ml) and transferred
to a scintillation vial for storage. The specific activity was 2.9 Ci/mol.
In Vitro Incubation Conditions. Incubations (150 ml) contained HLMs (500–
1500 mg microsomal protein/ml), potassium phosphate buffer (50 mM, pH 7.4),
MgCl2 (3 mM), EDTA (1 mM), and [
14C]-TMP (50–250 mM). The first step in
setting up incubations involved transferring the required amount of [14C]-TMP into
the tubes using 50 ml methanol, which was then removed by evaporation under a
gentle stream of nitrogen. After adding the other components, reactionswere initiated
by the addition of 15 ml of a NADPH-generating system consisting of NADP
(10 mM), glucose 6-phosphate (50 mM), and glucose-6-phosphate dehydrogenase
(10 U/ml). Reactions were incubated in a shaking water bath at 37 6 1C for
45–120 minutes. Incubations without the addition of NADPH were performed to
control for background nonspecific covalent binding. All incubations were run in
duplicate. For measurement of TMP metabolites covalently bound to protein,
aliquots (100ml) of the incubation mixture were applied toWhatman 3MM (Sigma-
Aldrich) absorbent filter paper strips cut to fit into scintillation vials (11  75 mm).
Strips were air-dried and then washed by immersion for 10215 minutes in each of a
series of five baths (130 ml each) composed of 10% trichloroacetic acid, 10%
trichloroacetic acid again, 95% ethanol, 95% ethanol again, and finally ethyl acetate.
After all washes, the strips were air-dried and submitted to liquid scintillation counting
(Wallin et al., 1981; Dansette et al., 1991).
[14C]-TMP Covalent Binding Inhibition Experiments. Incubations
(1500mgmicrosomal protein/ml, [14C]-TMP100mM, 120minutes) were performed
in the presence and absence of NAC (5mM) or NAL (5mM) to determine the extent
of covalent binding inhibition and implicate the putative covalent binding site as
cysteine and/or lysine. Net covalent binding was also determined in the presence
and absence of selective P450 inhibitors including thiotepa (CYP2B6, 50 mM),
montelukast (CYP2C8, 5 mM), sulfaphenazole (CYP2C9, 10 mM), benzylnirvanol
(CYP2C19, 10 mM), quinidine (CYP2D6, 5 mM), and ketoconazole (CYP3A4,
1 mM). 1-Benzylimidazole (1 mM) was used as a nonspecific P450 inhibitor.
Inhibitor concentrations were approximately 30 times Ki. Inhibition experi-
ments were performed in triplicate or quadruplicate.
Data Analysis.Correlation coefficients (r) between [14C]-TMPprotein covalent
binding and incubation conditions (TMP concentration, protein concentration, and
incubation time) were determined using least-squares regression analysis. Signif-
icance was determined by Pearson’s regression analysis using a two-tailed t test
with a equal to 0.05 by using GraphPad software (GraphPad Software Inc., La
Jolla, CA). Effects of NAC, NAL, and the selective P450 inhibitors were deter-
mined by comparing the amount of covalent binding expressed as a percentage of
the uninhibited control incubation.
Results and Discussion
In the presence of an NADPH-generating system, HLMs generated
measurable [14C]-TMP protein covalent binding up to 747 dpm/100 mg
protein, which equates to approximately 0.8 nmol Eq bound TMP/mg
protein. Covalent binding increased linearly with increasing TMP
concentration, protein concentration, and incubation time (Fig. 3). For
all incubations performed, nonspecific covalent binding observed in
the absence of NADPH and/or HLMs was subtracted to determine net
NADPH-dependent covalent binding (Fig. 4).
The presence of NAC (5 mM) decreased the amount of covalent
binding by 73% (P , 0.005), whereas NAL had no effect on covalent
binding of TMP (Fig. 3). Net TMP covalent binding was completely
abolished with the addition of 1-benzylimidazole, a potent P450 inhib-
itor that may affect various P450 isoforms. In addition, several isoform-
specific P450 inhibitors also significantly decreased the amount of
covalent binding (Fig. 5). Thiotepa (a selective CYP2B6 inhibitor) and
ketoconazole (a selective CYP3A4 inhibitor) inhibited TMP covalent
binding by 64% and 51%, respectively (P , 0.05). Sulfaphenazole (a
selective CYP2C9 inhibitor) inhibited TMP covalent binding by 34%,
but this was not significant (P = 0.10).
The results presented here demonstrate several important findings.
First, TMP metabolites definitely become covalently bound to pro-
teins when TMP is incubated with HLMs, and the amount of covalent
Fig. 1. Proposed pathway of TMP bioactivation and protein
covalent binding.
Fig. 2. Structure, synthesis, and labeling of [14C]-TMP. The black
dot indicates the position of the 14C label.
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binding observed increases linearly with increases in incubation time,
TMP concentration, and protein concentration. Second, the addition of
5 mM NAC significantly inhibited TMP protein covalent binding,
whereas 5 mM NAL had no effect, thus implicating protein sulfhydryl
groups as the likely target sites in proteins. Third, the selective inhibition
of CYP2B6 or CYP3A4 significantly decreases the observed amount of
TMP covalent binding.
Themaximum covalent binding detected after incubations of [14C]-TMP
with HLMswas 0.8 nmol Eq/mg protein. This amount of covalent binding
is comparable or greater than that reported for other drugs that are known
to undergo bioactivation followed by protein covalent binding and
subsequent adverse drug reactions (ADRs), including benzbromarone
(0.39 nmol Eq/mg protein) (Takakusa et al., 2008), acetaminophen
(0.09 nmol Eq/mg protein) (Nakayama et al., 2009), and flutamide
(0.18 nmol Eq/mg protein) (Nakayama et al., 2009). It has been proposed
that the covalent binding of chemically reactive metabolites to cellular
proteins could result in direct organ toxicity as well as the formation
of neoantigens that result in immune or even autoimmune reactivity (Koen
et al., 2012). Interestingly, our results demonstrate that TMP has higher
covalent binding capabilities in vitro with HLM incubations than
previously observed with SMX (0.003 nmol Eq/mg protein) (Nakayama
et al., 2009).
Until now, the ADRs observed with TMP-SMX have been attributed
solely to the SMX component (or its metabolites), but our results show
that TMP undergoes metabolic activation and covalent binding at least
as efficiently as SMX and several other hepatotoxic drugs (Cheng et al.,
2008). Our findings support the hypothesis that TMP has the poten-
tial to contribute to IADR development in these patients exposed to
TMP-SMX via the pathway of bioactivation followed by protein adduct
formation.
Modest concentrations of NAC (a soft nucleophile similar to gluta-
thione) significantly inhibited TMP covalent binding, suggesting that
protein covalent binding of TMP likely occurs on cysteine residues,
whereas no inhibition was observed in the presence of NAL (a hard
nucleophile). The observed effect of NAC on TMP covalent binding
suggests that glutathione has the ability to decrease covalent binding of
Fig. 3. Effects of TMP concentration, protein concentration, incubation time, and NAC on the covalent binding of [14C]-TMP to HLMs. Pooled HLMs from 16 donors were
incubated in the presence of NADPH at 37 6 1C. (A) TMP concentration ranged from 50 to 250 mM, whereas protein and time were constant at 1500 mg/ml protein and
120 minutes, respectively. (B) Protein concentrations ranged from 250 to 1500 mg/ml, whereas incubation time (120 minutes) and TMP (100 mM) were constant. (C)
Incubation times ranged from 45 to 120 minutes, while protein (1500 mg/ml) and TMP (100 mM) concentrations were constant. (D) NAC (5 mM) was included in the
incubation (100 mM TMP, 1500 mg protein/ml, 120 minutes). An aliquot (100 ml) of the incubation mixture was applied to absorbent filter paper strips and the strips were
processed as outlined in the Materials and Methods. Radioactivity associated with the precipitated protein was estimated by liquid scintillation counting. CVB, covalent
binding.
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TMP metabolites to protein. In vivo, the scavenging of reactive TMP
metabolites by glutathione probably serves as a protective mechanism
(Haouzi et al., 2000; Jaeschke et al., 2002) as well as a route to the
formation of urinary mercapturic acids. Our previous findings revealed
that all TMP-exposed individuals bioactivate TMP to some extent, as
shown by their urinary excretion of TMP mercapturic acids (van
Haandel et al., 2014). In addition, we found a 17-fold variation in
TMP mercapturic acid formation among individual HLM preparations
used in previous phenotyping experiments when NAC was added,
suggesting that variability of bioactivation and protein covalent binding
likely occurs in vivo (Goldman et al., 2015). However, the occurrence
and extent of TMP protein adduct formation had not been determined
until now.
With the inhibition of CYP2B6 and CYP3A4, a greater than 50% net
decrease in TMP covalent binding was observed. These findings are in
agreement with our previouswork usingHLMs, individual P450 isoforms,
and isoform-selective P450 inhibitors, which revealed CYP3A4 as the
isoform most strongly correlated with TMP-NAC generation (Goldman
et al., 2015). We also found that the CYP2B6 inhibitor thiotepa inhibited
TMP-NAC formation at the highest concentration used (150 mM), even
though recombinant CYP2B6 did not appear to catalyze TMP-NAC
formation (Goldman et al., 2015). This could be attributable to the fact that
thiotepa is also known to be a mechanism-based inactivator of CYP3A
enzymes. The high interindividual variation in TMP-mercapturate forma-
tion in HLMs supplemented with NAC may lead to differences in the
extent of TMP covalent binding, and this may be directly or indirectly
related to the idiosyncratic development of ADRs (Ozdemir et al., 2000;
Lamba et al., 2010).
In summary, based on the extent of TMP protein adduct formation
observed, further investigation of the role of protein covalent binding of
TMP metabolites in the generation of IADRs is clearly warranted. A better
understanding of the mechanisms associated with TMP covalent binding
in vivo and potential downstream immune stimulation may provide
predictive insight into which individuals are at greatest risk of developing
an IADR. Currently, the extent of TMP protein adduct formation in vivo,
and whether patients who develop an IADR have more extensive protein
adduct formation, remains unknown.
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Fig. 5. Effects of various P450 isoform-selective inhib-
itors on the covalent binding of [14C]-TMP to pooled
HLMs were analyzed as described in the Materials and
Methods. Each bar represents the mean and standard
deviation. CVB, covalent binding.
Fig. 4. Effect of NADPH on the covalent binding of [14C]-TMP to HLMs. Pooled
HLMs were incubated under standard conditions in the absence or presence of
NADPH, with [14C]-TMP (50–250 mM) at 37 6 1C for 120 minutes. An aliquot
(100 ml) of the incubation mixture was applied to absorbent filter paper strips as
outlined in the Materials and Methods. Radioactivity associated with the
precipitated protein was estimated by liquid scintillation counting. A low level of
apparent covalent binding was noted in those incubations without NADPH and this
amount was considered background and subtracted. CVB, covalent binding.
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